By CE2026-06-02T12:19:00
Agreement to develop and commercialise long-acting GLP drug candidate by South Korea-based biopharma company.
Lilly is adding another medicine to its growing GLP portfolio by licensing a novel long-acting glucagon-like peptide 2 (GLP-2) biologic from Hanmi Pharm, for up to $1.26 billion.
While Hanmi Pharm’s sonefpeglutide (LAPSGLP-2 analog) is being evaluated in an ongoing phase II trial in short bowel syndrome (SBS), Lilly’s current GLP roster for obesity and diabetes includes blockbuster drugs
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-07-20T13:48:00Z
2026-05-27T11:39:00Z
2026-03-18T15:00:00
Sponsored by Sartorius
2026-05-13T14:00:00
Sponsored by Thermo Fisher Scientific
2026-08-03T08:39:00
Sponsored by Shimadzu
2026-06-10T15:00:00
Sponsored by BioDuro
2026-09-16T15:00:00
Sponsored by BioDuro
Site powered by Webvision Cloud